42 results about "Glycocalyx" patented technology

A scientific computer system with processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are reprogrammed from cancer cell communication signals.

Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

A new indication of vitamin K is disclosed which results in the provision of methods of treatment, both therapeutic and non-therapeutic, as well as functional foods and pharmaceutical and nutraceutical products comprising vitamin K for improving microvascular integrity and capillary structure and function, thus preventing, mitigating, counteracting or curing diseases associated with impaired capillary morphology including the glycocalyx or capillary dysfunction. Preferably, vitamin K is a menaquinone, most preferably selected from the long-chain menaquinones MK-7 through MK-10.

A hybrid scientific computer system with processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. Confounding electrical signals are stored in a scientific cancer cell signal processor of the computer system. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are re-programmed from cancer cell communication signals.

A hybrid scientific computer system with processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. Confounding electrical signals are stored in a scientific cancer cell signal processor of the computer system. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are re-programmed from cancer cell communication signals.

The present invention relates to a substantially planar substrate for use in patch clamp analysis of the electrophysiological properties of a cell membrane comprising a glycocalyx, wherein the substrate comprises an aperture having a rim, the rim being adapted to form a gigaseal upon contact with the cell membrane. The invention further provides a method of making such a substrate and method for analysing the electrophysiological properties of a cell membrane comprising a glycocalyx.

A scientific computer system with processor capable of recording, storing and reprogramming the natural electrical signals of cancer cells as found in tumors of humans and animals. The reprogramming process is designed to create a confounding electrical signal for retransmission into a malignant tumor to damage or shut-down the cellular internal electrical communication system. Altering the electrical charge on the glycocalyx of the outer cell membrane is also part of the treatment by application of ions. The invention causes cancer cell death as a medical treatment using ultra-low voltage and amperage encoded signals which are reprogrammed from cancer cell communication signals.

The present invention relates to a substantially planar substrate for use in patch clamp analysis of the electrophysiological properties of a cell membrane comprising a glycocalyx, wherein the substrate comprises an aperture having a rim, the rim being adapted to form a gigaseal upon contact with the cell membrane, The invention further provides a method of making such a substrate and method for analysing the electrophysiological properties of a cell membrane comprising a glycocalyx.

The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy.

A bioadhesive composition for bonding together adjacent surfaces of wood comprises a microbially-produced fermentation residue containing adherent microbial cells and glycocalyx. This residue finds particular application as a replacement for a significant amount of phenol-formaldehyde (PF) or other conventional adhesive component commonly used in the production of plywood and other wood products.

Disclosed are methods and compositions for the treatment of a variety of disorders in subjects by affecting the glycocalyx of a subject in need of such treatment. The methods comprise administering to a subject an effective amount of a sulfated polysaccharide (SP) or analogue thereof, the SP being a non-animal based (e.g., plant, or bacteria derived) sulfated polysaccharide. The SPs can be administered as single agents, or in combination with one another, or with other medications to promote efficacy. Pharmaceutical compositions and comestibles including such SPs are also described.

A bioadhesive composition for bonding together adjacent surfaces of wood comprises a microbially-produced fermentation residue containing adherent microbial cells and glycocalyx. This residue finds particular application as a replacement for a significant amount of phenol-formaldehyde (PF) or other conventional adhesive component commonly used in the production of plywood and other wood products.

A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

Disclosed is a medicament for treating AIDS, wherein the active constituents include Fucoidan-Glycocalyx polymeric compound, which is a protein polysaccharide containing sulfate groups extracted from Chinese herbal sea apron. The preparing process consists of steps of choosing materials, soaking and cleaning, disintegrating, water extracting, low concentration alcohol depositing, high concentration depositing, purifying to obtain the end product.

The invention provides an application of neferine in the prevention or treatment of acute respiratory distress syndrome (ARDS). The neferine is alkaloid extracted from natural plants and has antioxidant activity. Based on the construction of animal and cell damage models of acute respiratory distress syndrome, by HE, Evan blue staining, fluorescent probe, immunofluorescence labeling and the like, it is verified that the neferine can reduce the production and release of reactive oxygen species (ROS) and reduce the degradation of vascular endothelium polysaccharide coating (Glycocalyx), thus the occurrence and development of ARDS are inhibited, and ARDS is prevented or treated.

A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.

The invention relates to a willow needle mushroom glycocalyx, as well as a preparation method and application thereof, and belongs to the field of natural medicine development. The preparation method comprises the following steps: inoculating willow needle mushroom seeds into a culture medium, wherein the culture conditions such as temperature, rotational speed and time are 22 to 26 DEG C, 120 to 160 r / min, and 5 to 6 days respectively; inoculating 10 to 20 percent inoculum concentration of the willow needle mushroom seeds into a fermentation culture medium, wherein the fermentation conditions such as temperature, rotational speed and time are 22 to 26 DEG C, 120 to 160 r / min, and 5 to 6 days respectively; carrying out centrifugation to collect a supernatant at the rotational speed of 4000 r / min to 6000 r / min; carrying out rotary evaporation and concentration till the volume is 1 / 10 to 1 / 8 of the original volume; adding anhydrous ethanol of which the volume is 3 to 5 times of the concentrated liquid at the temperature of 4 DEG C for 12 to 16 hours' precipitation; carrying out 10 to 20 minutes' centrifugation, wherein the rotational speed is 3000 to 5000 r / min; collecting the precipitate; drying the precipitate at 45 to 50 DEG C. The willow needle mushroom glycocalyx fills up the blank of resource development and utilization of willow needle mushroom in the market. Moreover, an important foundation for deep development of polysaccharide immunological accelerator medicine and health foods with immunomodulatory effects is provided, and the economic value and the marketable value are high.

A composition for treating multiple disease causes including a glycocalyx restoring and maintaining compound in an oral dosage form. A method of treating cardiovascular disease (CVD), by administering a glycocalyx restoring and maintaining compound to an individual suffering from CVD, restoring the glycocalyx, reversing inflammation, and reversing oxidative damage.

The present invention relates to a clonally pure population of serosal cancer stem cells (CSCs) as well as methods of producing and culturing the CSCs and uses thereof. The CSCs form catenae (free floating chains of cells) which have a glycocalyx coat of hyaluronan and proteoglycans. This discovery has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of glycocalyx formation, including combination therapies using chemotherapeutics in conjunction with glycocalyx inhibitors. The invention also provides drug screening assays for identifying compounds effective against these CSCs as well as other serosal cancer cells. Methods to use catena gene signatures, protein and surface antigens are provided for monitoring patient samples for the presence of serosal cancer stem cells.

The present invention relates to a method of predicting endometrial receptivity of an embryo implantation in a subject, the method comprising determining a level of podocalyxin in endometrial epithelial cells in the subject. The invention also relates to methods of monitoring epithelial cell receptivity and improving epithelial cell receptivity.

The invention relates to application of anisodamine or a pharmaceutically acceptable salt thereof in preparation of a cell glycocalyx protective agent, in particular to application of the anisodamineor the pharmaceutically acceptable salt thereof serving as the cell glycocalyx protective agent in recovery and protection of cell glycocalyx and cell adhesion. The application of the anisodamine or the pharmaceutically acceptable salt thereof in preparation of the cell glycocalyx protective agent also has the effect of protecting endothelial cell structures and functions.

A biomarker panel including a four-panel test for clotting that detects soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), and plasminogen activator inhibitor (PAI-1). A biomarker panel including a three-panel test for glycocalyx integrity that detects syndecan-1 (SDC1), heparan sulfate (HS), and hyaluronidase (HAD). A biomarker panel including a test that detects a biomarker chosen from soluble fibrin (SF), thrombin-antithrombin complex (TAT), antithrombin III (ATIII), plasminogen activator inhibitor (PAI-1), syndecan-1 (SDC1), heparan sulfate (HS), hyaluronidase (HAD), and combinations thereof. A kit including a biomarker panel, instructions for use, materials to take and apply samples to the panel, and descriptions of biomarker levels and their meaning. Methods of detecting the presence of vascular disease, determining the stage of vascular disease, monitoring the progress of vascular disease treatments, and monitoring the efficacy of drugs during drug development.

This invention relates to a medicine for chronic renal failure and its preparation method, and belongs to the technology field of preparing medicine for treating chronic renal failure. The medicine is characterized in comprising the active constituent of F-Glycocalyx which is the valid target of ecklonia kurome and is protein polysaccharides containing sulfate group extracted from ecklonia kurome. the preparation method of F-Glycocalyx comprise (1) selecting, (2) soaking and cleaning, (3) pulverizing, (4) extracting with water, (5) precipitating with alcohol of low concentration, (6)precipitating with alcohol of high concentration, and (7) purifying to obtain purified product, drying, and packaging. The inventive medicine can effectively inhibit malignant tumor viral, improve immunity with no toxicity and adverse side effect, no untoward reaction and low cost.

The invention relates to a polysaccharide-protein complex of Flammulina velutipes and its preparation method and application, and belongs to the field of natural medicine development. Inoculate the strain of Flammulina velutipes in the seed culture medium. The culture conditions are: temperature 22-26°C, rotation speed 120-160r / min. After 5-6 days of cultivation, 10-20% of the inoculation amount is inserted into the fermentation medium. The fermentation conditions It is: temperature 22-26°C, rotation speed 120-160r / min, after culturing for 5-6 days, centrifuge at 4000r / min-6000r / min to collect the supernatant, and concentrate it to 1 / 10-1 / 8 of the original volume by rotary evaporation. Add 3-5 times the volume of absolute ethanol to precipitate at 4°C for 12-16h, centrifuge for 10-20min at a speed of 3000-5000r / min, collect the precipitate, and dry at 45-50°C. The invention fills up the gap in the development and utilization of Flammulina velutipes resources in the market. At the same time, it provides an important foundation for the in-depth development of polysaccharide immunostimulant drugs and health food with immunoregulatory effects, and has important economic and market value.

This invention relates to a medicine for improving immunity and treating malignant tumor and its preparation method, and belongs to the technology field of preparing medicine for treating malignant tumor. The medicine is characterized in comprising the active constituent of F-Glycocalyx which is the valid target of ecklonia kurome and is protein polysaccharides containing sulfate group extracted from ecklonia kurome. the preparation method of F-Glycocalyx comprise (1) selecting, (2) soaking and cleaning, (3) pulverizing, (4) extracting with water, (5) precipitating with alcohol of low concentration, (6) precipitating with alcohol of high concentration, and (7) purifying to obtain purified product, drying, and packaging. The inventive medicine can effectively inhibit malignant tumor viral, improve immunity with no toxicity and adverse side effect, no untoward reaction and low cost.

The invention is directed to the use of glycosaminoglycans for restoring glycocalyx functions or preventing glycocalyx damage. The effectiveness of glycosaminoglycans is directed in all pathologies where glycocalyx damage or this function may be etiologically cause of many pathologies such as: vascular disease, septic states, atherosclerosis syndrome, inflammation states and disease related to ischemia, peritoneal impairment, myocardial infarction, cerebrum- vascular events, alteration of enzymatic glycosylation in diabetes, kidney injury, intestinal disease as ulcerous colitis conditions, pneumoconiosis involving alteration of metabolic activity of pulmonary endothelium.

Provided herein are selectin-binding peptide ligands having both D- and L-amino acids, and peptide conjugates including the provided peptide ligands. The peptide conjugates can include a biopolymer backbone, such as dermatan sulfate, and 33 or fewer peptide ligands conjugated to the biopolymer. Also provided are methods for using the provided peptide conjugates to treat patients suffering from endothelial dysfunction.

Provided is a drug which improves the absorption efficiency of a drug from the mucosal epithelium. This transmucosal administration agent contains, as an active ingredient, an agent compound to which a podocalyxin target molecule is bound.

SCGB-based preparations and methods to use these preparations to protect the glycocalyx in medical, veterinary, and cosmetic applications are provided. The secretoglobins (SCGBs) are a family of small secreted globular proteins present in all mammals and sharing conserved structure and thought to share similar immunomodulatory functions. Heparan sulfate proteoglycan proteins (HSPGs) are expressed on the outer membranes of cells and have carbohydrate side chains that, together, make up the glycocalyx. The glycocalyx is a protective layer surrounding all cells, acting as a filter regulating the passage of nutrients into the cell and modifying cell signaling by external factors. There are two major families of HSPGs including syndecans and glypicans, plus several other HSPGs in all mammals. SCGBs bind to, and interact with, HSPGs to further modulate cell signaling and cellular responses to external factors.